ADC Therapeutics SA last reported quarterly results on Oct 13, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026). It usually reports 8–44 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 7, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Jan 8, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 8–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 13, 2026
13 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
—
|
—
|
|
Aug 13, 2026
44 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
19
+3.0%
|
-17
+70.8%
|
-0.11
+78.0%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
20
+15.1%
|
-33
+14.6%
|
-0.21
+41.7%
|
|
Jan 8, 2026
8 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
23
+36.4%
|
-6
+79.1%
|
-0.04
+85.4%
|
|
Oct 14, 2025
14 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
16
-12.6%
|
-41
+6.8%
|
-0.30
+28.6%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
18
+6.2%
|
-57
-55.0%
|
-0.50
-31.6%
|
|
May 14, 2025
44 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
17
-2.5%
|
-39
+17.2%
|
-0.36
+35.7%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
17
|
-31
|
-0.29
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADCT (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Epalinges, Switzerland
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1771910
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.